
Syngene expands global footprint with $36.5m Baltimore bet
Syngene International, the contract development and manufacturing organization (CDMO) arm of Biocon, has acquired a biologics site in Bayview, Baltimore, Maryland to manufacture monoclonal antibodies (mAbs). With a total investment of $50 million, …